Clinical Trial Update: A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating chemotherapy with or without INCB161734 in untreated metastatic pancreatic ductal adenocarcinoma with KRAS G12D mutation is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• INCB161734

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors | Phase 3 | Status: RECRUITING